Flamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1
LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA , June 10, 2024 /PRNewswire/ — Flamingo Therapeutics (“Flamingo”) today announced a poster presentation on…
